[18F]Florbetapir PET识别包涵体肌炎肌肉淀粉样变并区分多发性肌炎
英国一家成人神经肌肉中心的观察性研究纳入10例包涵体肌炎(IBM)和6例多发性肌炎(PM)患者,行[18F]florbetapir PET及骨骼肌MRI。IBM各感兴趣区[18F]florbetapir标准化摄取比值均显著高于PM,总比值≥1.28时诊断IBM的敏感度80%、特异度100%,提示该显像可区分IBM与PM。
要点
- IBM患者骨骼肌[18F]florbetapir标准化摄取比值显著高于PM患者。
- 总标准化摄取比值≥1.28诊断IBM的敏感度80%、特异度100%。
- 该显像有望辅助IBM准确诊断并减少不必要的有害治疗暴露。
核心结论
- [18F]florbetapir淀粉样蛋白PET可将包涵体肌炎与多发性肌炎区分开。
研究设计与样本
- 英国成人神经肌肉中心的观察性研究,纳入10例IBM和6例PM患者,行临床评估、[18F]florbetapir PET及骨骼肌MRI。
主要发现
- IBM所有评估区域的[18F]florbetapir标准化摄取比值均显著高于PM,总比值1.45(1.28至2.05)对1.01(0.80至1.22),p=0.005。
- 研究评估了[18F]florbetapir标准化摄取比值与临床及MRI疾病严重程度指标的关系。
关键数值与推荐
- 总[18F]florbetapir标准化摄取比值≥1.28时,诊断IBM的敏感度为80%、特异度为100%。
临床怎么用
- 对临床疑诊IBM而难以与PM鉴别的患者,可考虑[18F]florbetapir PET辅助诊断。
- 明确诊断有助于患者纳入临床试验,并避免不必要的潜在有害治疗。
局限性
- 样本量小(IBM 10例、PM 6例),为单中心观察性研究,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: With the tools available currently, confirming the diagnosis of inclusion body myositis (IBM) can be difficult. Many patients are initially misdiagnosed with polymyositis (PM). In this observational study at a UK adult neuromuscular centre, we investigated whether amyloid positron emission tomography could differentiate between IBM and PM. METHODS: Ten patients with IBM and six with PM underwent clinical review, [18F]florbetapir positron emission tomography and MRI of skeletal musculature. Differences in [18F]florbetapir standardised uptake value ratios in skeletal muscle regions of interest were evaluated. Relationships between [18F]florbetapir standardised uptake value ratios and measures of disease severity (clinical and by MRI of skeletal muscle) were assessed. RESULTS: [18F]florbetapir standardised uptake value ratios were significantly higher in those with IBM compared with PM for all assessed regions (total-[18F]florbetapir standardised uptake value ratio 1.45 (1.28 to 2.05) vs 1.01 (0.80 to 1.22), p=0.005). For total-[18F]florbetapir standardised uptake value ratios≥1.28, sensitivity and specificity for IBM was 80% and 100%, respectively. CONCLUSIONS: [18F]florbetapir amyloid positron emission tomography differentiates IBM from PM. Successful development could facilitate accurate diagnosis, inclusion in clinical trials and help avoid unnecessary exposure to potentially harmful treatments.
引用
- Lilleker JB, Hodgson R, Roberts M, et al. [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann Rheum Dis. 2019. PMID: 30760470. doi:10.1136/annrheumdis-2018-214644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。